159 related articles for article (PubMed ID: 38491829)
21. A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer.
LaVigne K; Hyman DM; Zhou QC; Iasonos A; Tew WP; Aghajanian C; Makker V; Hensley ML; Konner J; Grisham RN; Cangemi N; Soldan K; Spriggs DR; Sabbatini PJ; OʼCearbhaill RE
Int J Gynecol Cancer; 2018 Jul; 28(6):1176-1182. PubMed ID: 29757876
[TBL] [Abstract][Full Text] [Related]
22. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience.
Polyzos A; Tsavaris N; Kosmas C; Arnaouti T; Kalahanis N; Tsigris C; Giannopoulos A; Karatzas G; Giannikos L; Sfikakis PP
Oncology; 2001; 61(2):129-33. PubMed ID: 11528251
[TBL] [Abstract][Full Text] [Related]
23. 4-step, 2-h carboplatin desensitization in Japanese patients with ovarian cancer: a prospective study.
Nishimura M; Sakai H; Onoe T; Boku S; Yokoyama T; Kadokura G; Morita S; Katsumata N; Matsumoto K
Int J Clin Oncol; 2021 Aug; 26(8):1553-1560. PubMed ID: 34037884
[TBL] [Abstract][Full Text] [Related]
24. Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study.
Paksoy N; Khanmammadov N; Doğan İ; Ferhatoğlu F; Yildiz A; Ak N; Aydiner A
Medicine (Baltimore); 2022 Nov; 101(45):e31726. PubMed ID: 36397338
[TBL] [Abstract][Full Text] [Related]
25. Risk-stratification protocol for carboplatin and oxaliplatin hypersensitivity: repeat skin testing to identify drug allergy.
Wang AL; Patil SU; Long AA; Banerji A
Ann Allergy Asthma Immunol; 2015 Nov; 115(5):422-8. PubMed ID: 26298407
[TBL] [Abstract][Full Text] [Related]
26. Prophylactic 3-hour graduated infusion schedule minimizes risk of carboplatin hypersensitivity reactions - A prospective study.
Koul A; Forsland EL; Bjurberg M
Gynecol Oncol; 2018 Feb; 148(2):363-367. PubMed ID: 29208369
[TBL] [Abstract][Full Text] [Related]
27. A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions.
Patil SU; Long AA; Ling M; Wilson MT; Hesterberg P; Wong JT; Banerji A
J Allergy Clin Immunol; 2012 Feb; 129(2):443-7. PubMed ID: 22099941
[TBL] [Abstract][Full Text] [Related]
28. Simplified Graded Infusion Strategy for Mitigation of Oxaliplatin Hypersensitivity.
Alonso Martinez S; Segal NH; Cercek A; Yaeger R; Stadler Z; Kemeny NE; Nusrat M; Shahrokni A; Connell L; Saltz LB
Clin Colorectal Cancer; 2022 Jun; 21(2):149-153. PubMed ID: 35125319
[TBL] [Abstract][Full Text] [Related]
29. Carboplatin hypersensitivity reactions.
Winkeljohn D; Polovich M
Clin J Oncol Nurs; 2006 Oct; 10(5):595-8. PubMed ID: 17063613
[TBL] [Abstract][Full Text] [Related]
30. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital.
Schwartz JR; Bandera C; Bradley A; Brard L; Legare R; Granai CO; Dizon DS
Gynecol Oncol; 2007 Apr; 105(1):81-3. PubMed ID: 17157366
[TBL] [Abstract][Full Text] [Related]
31. Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions.
Maurer K; Michener C; Mahdi H; Rose PG
J Gynecol Oncol; 2017 Jul; 28(4):e38. PubMed ID: 28541630
[TBL] [Abstract][Full Text] [Related]
32. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments.
Feldweg AM; Lee CW; Matulonis UA; Castells M
Gynecol Oncol; 2005 Mar; 96(3):824-9. PubMed ID: 15721432
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of a Undiluted, One-Bag Desensitization Protocol for Chemotherapeutic Agents.
Iglesias-Santamaría A; Castellano Copa P
Ann Pharmacother; 2023 Jan; 57(1):55-61. PubMed ID: 35570798
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of hypersensitivity reactions to cancer chemotherapeutic agents in pediatric patients.
Turgay Yagmur I; Guzelkucuk Z; Yarali N; Ozyoruk D; Toyran M; Civelek E; Ozbek NY; Dibek Misirlioglu E
Ann Allergy Asthma Immunol; 2020 Apr; 124(4):350-356. PubMed ID: 31981613
[TBL] [Abstract][Full Text] [Related]
35. Readministration of Platinum Agents in Recurrent Ovarian Cancer Patients Who Developed Hypersensitivity Reactions to Carboplatin.
Narui C; Tanabe H; Shapiro JS; Nagayoshi Y; Maruta T; Inoue M; Hirata Y; Komazaki H; Takano H; Niimi S; Isonishi S; Okamoto A
In Vivo; 2019; 33(6):2045-2050. PubMed ID: 31662536
[TBL] [Abstract][Full Text] [Related]
36. Incidence of and risk factors associated with nedaplatin-related hypersensitivity reactions.
Kawarada Y; Miyazaki M; Itoh A; Araki R; Iwamizu H; Kataoka T; Kumakura Y; Ota A; Nagai T; Yamada K
Int J Clin Oncol; 2017 Jun; 22(3):593-599. PubMed ID: 28124284
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.
Bergamini A; Pisano C; Di Napoli M; Arenare L; Della Pepa C; Tambaro R; Facchini G; Gargiulo P; Rossetti S; Mangili G; Pignata S; Cecere SC
Gynecol Oncol; 2017 Jan; 144(1):72-76. PubMed ID: 28094039
[TBL] [Abstract][Full Text] [Related]
38. Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization.
Wong JT; Ling M; Patil S; Banerji A; Long A
J Allergy Clin Immunol Pract; 2014; 2(1):40-5. PubMed ID: 24565767
[TBL] [Abstract][Full Text] [Related]
39. Rapid Drug Desensitization with Chemotherapeutics (Platins, Taxanes, and Others): A Single-Center Retrospective Study.
Kendirlinan R; Gümüşburun R; Çerçi P; Özbek E; Altıner S; Çelebi Sözener Z; Soyyiğit Ş; Aydın Ö; Bavbek S
Int Arch Allergy Immunol; 2019; 179(2):114-122. PubMed ID: 30893688
[TBL] [Abstract][Full Text] [Related]
40. Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol.
Syrigou EI; Karapanagiotou EM; Alamara CV; Boura PG; Saif MW; Syrigos KN
Clin Colorectal Cancer; 2009 Apr; 8(2):106-9. PubMed ID: 19739272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
